Developing macromolecular therapeutics: the future drug-of-choice

He, Huining; Dong, Weibing; Gong, Junbo; Wang, Jingkang; Yang, Victor C.

doi:10.1007/s11705-009-0291-5

Cited by 8 publications

(1 citation statement)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, various classes of CPPs, including arginine/lysine-rich cationic peptides, LMWP, Penetratin and VP22 [15,24,31,32,33,34], as well as amphipathic peptides such as MAP, MPG, pep-1, etc., were also reported and utilized in either remarkable intracellular delivery strategies or the successful application in medical and biological field [17,19,25,26,27,35,36,37,38,39,40,41,42,43,44,45,46,47,48]. Via covalent linkage or non-covalent charge-associated aggregation, linkage, both in vitro and in vivo results demonstrated that CPPs could assist the delivery of virtually all types of molecular cargos including proteins [2,16,20,26,46,49,50,51,52,53,54,55], nucleic acids [33,35,36,56,57,58,59,60], and nano-carriers such as magnetic iron oxide nanoparticles (MION) [61,62,63,64,65,66,67,68] into cells.…”

Section: Cell Penetrating Peptides (Cpps)-assisted Strategies For mentioning

confidence: 99%

CPP-Assisted Intracellular Drug Delivery, What Is Next?

Liu

et al. 2016

IJMS

Self Cite

View full text Add to dashboard Cite

For the past 20 years, we have witnessed an unprecedented and, indeed, rather miraculous event of how cell-penetrating peptides (CPPs), the naturally originated penetrating enhancers, help overcome the membrane barrier that has hindered the access of bio-macromolecular compounds such as genes and proteins into cells, thereby denying their clinical potential to become potent anti-cancer drugs. By taking the advantage of the unique cell-translocation property of these short peptides, various payloads of proteins, nucleic acids, or even nanoparticle-based carriers were delivered into all cell types with unparalleled efficiency. However, non-specific CPP-mediated cell penetration into normal tissues can lead to widespread organ distribution of the payloads, thereby reducing the therapeutic efficacy of the drug and at the same time increasing the drug-induced toxic effects. In view of these challenges, we present herein a review of the new designs of CPP-linked vehicles and strategies to achieve highly effective yet less toxic chemotherapy in combating tumor oncology.

show abstract

Section: Cell Penetrating Peptides (Cpps)-assisted Strategies For mentioning

confidence: 99%

CPP-Assisted Intracellular Drug Delivery, What Is Next?

Liu

et al. 2016

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

Protein/peptide‐based entry/fusion inhibitors as anti‐HIV therapies: challenges and future direction

Fumakia

Yang

et al. 2015

Reviews in Medical Virology

View full text Add to dashboard Cite

The failures of several first-generation and second-generation small molecule drug-based anti-HIV therapies in various stages of clinical trials are an indication that there is a need for a paradigm shift in the future designs of anti-HIV therapeutics. Over the past several decades, various anti-HIV drugs have been developed, among them, protein/peptide-based therapies. From the first peptide discovered (SJ2176) to the first peptide approved by the Food and Drug Administration (DP178/T20/enfuvirtide/Fuzeon®), anti-HIV proteins/peptides as fusion/entry inhibitors have been shown to provide potent effects and benefits. This review summarizes the past and current endeavors in this area, discusses the potential mechanisms of action for various anti-HIV proteins/peptides, compares the advantages and disadvantages between the different proteins/peptides, and finally, examines the future direction of the field, specifically, strategies that will enhance the therapeutic efficacy of fusion/entry inhibitor-based anti-HIV proteins/peptides. Although there are numerous reviews highlighting the general field of entry/fusion inhibitors, there is a lack of literature focused on protein/peptide-based entry/fusion inhibitors for HIV therapy, and as a result, this review is intended to fill this void by summarizing the past, current, and future development of these macromolecules. Copyright © 2015 John Wiley & Sons, Ltd.

show abstract